You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 28 No. 5, May 1973 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Clinical Pharmacology of Imipramine

Implications for Therapeutics

Alexander H. Glassman, MD; James M. Perel, PhD

Arch Gen Psychiatry. 1973;28(5):649-653.


Abstract

In the last several years it has become apparent that identical oral doses of a tricyclic antidepressant can, in different individuals, result in radically different blood levels. This phenomenon which is the result of drug-drug interactions and individual genetic characteristics has major clinical implications. The plasma level resulting from a standard oral dose can be markedly increased or decreased by the concomitant administration of numerous usually used medications. This is a significant and commonly unrecognized problem and compounds the genetic metabolic variability inherent in these drugs.

In this review imipramine hydrochloride is used as a model for the tricyclic antidepressants in general. Its metabolism and pharmacodynamics are examined with specific emphasis on their relationship to the marked individual variability seen in this class of drugs and the relationship of this variability to clinical effectiveness.



Author Affiliations

New York

From the New York State Psychiatric Institute and the Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York.


Footnotes

Accepted for publication Jan 10, 1973.

Reprint requests to the New York State Psychiatric Institute, 722 W 168th St, New York, NY 10032 (Dr. Glassman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Novel Antidepressants and the Biogenic Amine Hypothesis of Depression: The Case for Iprindole and Mianserin
Zis and Goodwin
Arch Gen Psychiatry 1979;36:1097-1107.
ABSTRACT  

Withdrawal From Long-term High-Dose Desipramine Therapy: Clinical and Biological Changes
Brown et al.
Arch Gen Psychiatry 1978;35:1261-1264.
ABSTRACT  

Clinical Implications of Imipramine Plasma Levels for Depressive Illness
Glassman et al.
Arch Gen Psychiatry 1977;34:197-204.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1973 American Medical Association. All Rights Reserved.